nascobal (r) (b 12) demand is strong

Quote






Shopping for generic buyouts? Here's a list
June 8, 2010 — 10:50am ET | By Tracy Staton

Hear ye, hear ye: Any Big Pharma looking to snap up a generics maker has three options on offer this morning--and, as a blueprint, one behind-the-scenes look at how a recent emerging-markets generics deal went down.

First, there's Germany's Stada. The company announced yesterday that it plans to cut 10 percent of its workforce and double its profits. CEO Hartmut Retzlaff says that it is not only scouting for acquisitions of its own, but it's also open to buyout offers. The company has been named as a potential target for Pfizer (NYSE: PFE), which lost out to Teva Pharmaceutical Industries (NASDAQ: TEVA) in the bidding for Stada's German rival Ratiopharm.

Next, there are two Indian generics makers that analysts are tagging as likely buyouts. Dr. Reddy's Laboratories and Cipla--two of the country's biggest domestic drugmakers--are logical takeover targets for multinational drugmakers, First Global Securities says. And given the premium Abbott Laboratories paid to buy Piramal Healthcare, it appears that there's no shortage of potential buyers. Moreover, those buyers might be willing to pay plenty for a bigger footprint in India, which is one of the fastest-growing pharma markets in the world right now.

Finally, you'll want to explore just how that price for Piramal was set. MoneyControl offers a look at the deal from Piramal's point of view, in a story that includes a secret rendezvous in Dubai and a three-page note setting out Ajay Piramal's valuation of the division he'd end up selling to Abbott. "It took about four hours of my time," Piramal tells the magazine. May you be so lucky.

By Anonymous | Posted 12:37pm | June 8, 2010
Par Pharma is severly undervalued and with generic sales limited to the USA is attractive to foreign buyers looking for a USA footprint



Read more: Shopping for generic buyouts? Here's a list - FiercePharma http://www.fiercepharma.com/story/shopping-generic-buyouts-heres-list/2010-06-08#ixzz0qHVKRZcb
 




























































With nascobal setting internal sales records , one can only imagine oravig sales given Par's award winning highly skilled and motivated sales force. Bonuses galore Christmas 2010! Let's get the CP family together in 6 months to celebrate and get ready for the Strativa IPO in 2011.
 












Let's promise to do everything possible to save strativa


READ BELOW



Yesterday's press release about the Biovail-Valeant Pharmaceuticals merger didn't mention one key fact: Combining the two companies will lead to layoffs. Up to 20 percent of the combined workforce--or up to 870 jobs.

That's the word from incoming CEO Michael Pearson, who made the announcement during a conference call about the deal. In touting the $175 million in cost savings from the reverse merger--and the deal's ability to boost earnings per share within the first year--Pearson acknowledged that he'll have to reduce headcount to make those two things happen.

It is hardly novel that a merger leads to layoffs; indeed, one of the selling points of any deal is the costs that can be cut from overlapping functions. And those cuts usually include jobs. So when Pfizer and Wyeth announced their megamerger, they, too announced job cuts of up to 20 percent of their combined workforce, or 19,500. So did Merck and Schering-Plough, which aimed to eliminate some 16,000 jobs. When Roche bought the rest of Genentech it didn't already own, it started cutting jobs as well.

- read the story from Canoe




Read more: Biovail-Valeant combo to claim up to 870 jobs - FiercePharma http://www.fiercepharma.com/story/biovail-valeant-combo-claim-870-jobs/2010-06-22#ixzz0rbhcGcA5
Subscribe: http://www.fiercepharma.com/signup?sourceform=Viral-Tynt-FiercePharma-FiercePharma
 






Anonymous said:
Let's promise to do everything possible to save strativa


READ BELOW



Yesterday's press release about the Biovail-Valeant Pharmaceuticals merger didn't mention one key fact: Combining the two companies will lead to layoffs. Up to 20 percent of the combined workforce--or up to 870 jobs.

That's the word from incoming CEO Michael Pearson, who made the announcement during a conference call about the deal. In touting the $175 million in cost savings from the reverse merger--and the deal's ability to boost earnings per share within the first year--Pearson acknowledged that he'll have to reduce headcount to make those two things happen.

It is hardly novel that a merger leads to layoffs; indeed, one of the selling points of any deal is the costs that can be cut from overlapping functions. And those cuts usually include jobs. So when Pfizer and Wyeth announced their megamerger, they, too announced job cuts of up to 20 percent of their combined workforce, or 19,500. So did Merck and Schering-Plough, which aimed to eliminate some 16,000 jobs. When Roche bought the rest of Genentech it didn't already own, it started cutting jobs as well.

- read the story from Canoe




Read more: Biovail-Valeant combo to claim up to 870 jobs - FiercePharma http://www.fiercepharma.com/story/biovail-valeant-combo-claim-870-jobs/2010-06-22#ixzz0rbhcGcA5
Subscribe: http://www.fiercepharma.com/signup?sourceform=Viral-Tynt-FiercePharma-FiercePharma
Click to expand...

WHAT DID YOU EXPECT......THIS IS EXACTLY WHAT HAPPENS
 




































Top Bottom
Back
Quote